The neural basis of deficits in acquisition and extinction of fear in schizophren

精神分裂症患者恐惧获得和消除缺陷的神经基础

基本信息

  • 批准号:
    8436169
  • 负责人:
  • 金额:
    $ 50.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-03-01 至 2016-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): People who develop schizophrenia show deficits in emotional learning and memory, which have been linked to the symptoms of the disorder. Yet the neurobiological basis of these deficits is unknown. One challenging issue associated with this question is that the medications used to treat schizophrenia also cause some impairment in emotional function, so it has been difficult in previous studies to distinguish effects of the disorder from those of the medications used by the majority of the patients with the illness. One common method used to study emotional learning and memory in mammals, including humans, is called Pavlovian fear conditioning. In Pavlovian fear conditioning procedures, a person is exposed to a neutral stimulus, such as a tone or picture, which is followed by an unpleasant sensation, such as a loud noise or mild electrical stimulus. After a certain number of repetitions of this procedure, the person begins to experience some anticipatory anxiety or fear when exposed to the neutral stimulus by itself. A second type of learning can occur when this neutral stimulus is later presented several times without being followed by the unpleasant stimulus; this is called extinction learning and it requires the formation of a memory trace that is coded separately from the fear memory. These fear and extinction memories can be recalled at a later time, depending on the circumstances (called the "context") during the formation and recall of the memories. We have found evidence suggesting that the learning and later recall of fear and extinction memories is abnormal in schizophrenia. In this project, we will test the hypothesis that these abnormalities in fear and extinction learning and memory in schizophrenia are related to specific changes in the function of the brain regions known to drive these processes, and that these neural changes are linked to specific symptoms of schizophrenia. We will also determine whether any of the abnormalities in this system arise from, are worsened or improved by treatment with antipsychotic medications. This project has implications for understanding the fundamental pathophysiology of schizophrenia and for developing early markers and new treatments for the disorder. !
描述(申请人提供):精神分裂症患者在情绪学习和记忆方面表现出缺陷,这与该疾病的症状有关。然而,这些缺陷的神经生物学基础尚不清楚。与这个问题相关的一个具有挑战性的问题是,用于治疗精神分裂症的药物也会导致一些情绪功能障碍,因此在之前的研究中,很难区分这种障碍的影响与大多数患者使用的药物的影响。一种用于研究哺乳动物(包括人类)情绪学习和记忆的常用方法被称为巴甫洛夫恐惧条件反射。在巴甫洛夫式的恐惧条件作用过程中,一个人暴露在中性刺激下,如音调或图片,紧随其后的是不愉快的感觉,如巨大的噪音或轻微的电刺激。经过一定次数的重复这一过程后,人开始体验到一些预期的焦虑或恐惧,当暴露在中性刺激中时。第二种类型的学习可能会发生,当这种中性刺激随后出现几次而不是令人不快的刺激时;这被称为消退学习,它需要形成一种与恐惧记忆分开编码的记忆痕迹。这些恐惧和消亡的记忆可以在以后的时间被回忆起来,这取决于记忆形成和回忆过程中的环境(称为“背景”)。我们发现有证据表明,精神分裂症患者对恐惧和消亡记忆的学习和后来的回忆是不正常的。在这个项目中,我们将测试一种假设,即精神分裂症患者在恐惧和消退学习和记忆方面的这些异常与驱动这些过程的大脑区域功能的特定变化有关,并且这些神经变化与精神分裂症的特定症状有关。我们还将确定该系统中的任何异常是否由抗精神病药物治疗引起、恶化或改善。该项目对了解精神分裂症的基本病理生理学,以及开发该疾病的早期标志物和新的治疗方法具有重要意义。好了!

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAPHNE J HOLT其他文献

DAPHNE J HOLT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAPHNE J HOLT', 18)}}的其他基金

Neural mechanisms of social distance in psychosis
精神病中社交距离的神经机制
  • 批准号:
    9892275
  • 财政年份:
    2016
  • 资助金额:
    $ 50.46万
  • 项目类别:
Neural mechanisms of social distance in psychosis
精神病中社交距离的神经机制
  • 批准号:
    9237610
  • 财政年份:
    2016
  • 资助金额:
    $ 50.46万
  • 项目类别:
Neural mechanisms of social distance in psychosis
精神病中社交距离的神经机制
  • 批准号:
    9355697
  • 财政年份:
    2016
  • 资助金额:
    $ 50.46万
  • 项目类别:
The neural basis of deficits in acquisition and extinction of fear in schizophren
精神分裂症患者恐惧获得和消除缺陷的神经基础
  • 批准号:
    8218407
  • 财政年份:
    2012
  • 资助金额:
    $ 50.46万
  • 项目类别:
The neural basis of deficits in acquisition and extinction of fear in schizophren
精神分裂症患者恐惧获得和消除缺陷的神经基础
  • 批准号:
    8984915
  • 财政年份:
    2012
  • 资助金额:
    $ 50.46万
  • 项目类别:
The neural basis of deficits in acquisition and extinction of fear in schizophren
精神分裂症患者恐惧获得和消除缺陷的神经基础
  • 批准号:
    8789177
  • 财政年份:
    2012
  • 资助金额:
    $ 50.46万
  • 项目类别:
The Neural Basis of Delusions in Schizophrenia: Studies of Emotional Perception
精神分裂症妄想的神经基础:情绪感知的研究
  • 批准号:
    8032848
  • 财政年份:
    2010
  • 资助金额:
    $ 50.46万
  • 项目类别:
The Neural Basis of Delusions in Schizophrenia: Studies of Emotional Perception
精神分裂症妄想的神经基础:情绪感知的研究
  • 批准号:
    7281302
  • 财政年份:
    2006
  • 资助金额:
    $ 50.46万
  • 项目类别:
The Neural Basis of Delusions in Schizophrenia: Studies of Emotional Perception
精神分裂症妄想的神经基础:情绪感知的研究
  • 批准号:
    7907657
  • 财政年份:
    2006
  • 资助金额:
    $ 50.46万
  • 项目类别:
The Neural Basis of Delusions in Schizophrenia: Studies of Emotional Perception
精神分裂症妄想的神经基础:情绪感知的研究
  • 批准号:
    7487874
  • 财政年份:
    2006
  • 资助金额:
    $ 50.46万
  • 项目类别:

相似海外基金

Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10661090
  • 财政年份:
    2022
  • 资助金额:
    $ 50.46万
  • 项目类别:
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10501196
  • 财政年份:
    2022
  • 资助金额:
    $ 50.46万
  • 项目类别:
Possible mechanism of action of metabolic syndrome induction in patients treated with atypical antipsychotic agents
使用非典型抗精神病药物治疗的患者诱导代谢综合征的可能作用机制
  • 批准号:
    22590157
  • 财政年份:
    2010
  • 资助金额:
    $ 50.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The use of atypical antipsychotic agents and the risk of breast cancer
非典型抗精神病药物的使用和乳腺癌的风险
  • 批准号:
    192724
  • 财政年份:
    2009
  • 资助金额:
    $ 50.46万
  • 项目类别:
    Operating Grants
Indolobenzox- and Thiazepines as Atypical Antipsychotic Agents
吲哚苯氧和硫氮卓类药物作为非典型抗精神病药
  • 批准号:
    7539253
  • 财政年份:
    2008
  • 资助金额:
    $ 50.46万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7676049
  • 财政年份:
    2007
  • 资助金额:
    $ 50.46万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7626881
  • 财政年份:
    2007
  • 资助金额:
    $ 50.46万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7333930
  • 财政年份:
    2007
  • 资助金额:
    $ 50.46万
  • 项目类别:
Muscarinic receptor activators as antipsychotic agents
作为抗精神病药物的毒蕈碱受体激活剂
  • 批准号:
    7034693
  • 财政年份:
    2006
  • 资助金额:
    $ 50.46万
  • 项目类别:
Muscarinic receptor activators as novel antipsychotic agents
毒蕈碱受体激活剂作为新型抗精神病药
  • 批准号:
    7163800
  • 财政年份:
    2006
  • 资助金额:
    $ 50.46万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了